Logo image of BFRI

BIOFRONTERA INC (BFRI) Stock Fundamental Analysis

NASDAQ:BFRI - US09077D2099 - Common Stock

0.8499 USD
-0.04 (-4.09%)
Last: 9/2/2025, 1:48:41 PM
Fundamental Rating

2

Taking everything into account, BFRI scores 2 out of 10 in our fundamental rating. BFRI was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of BFRI have multiple concerns. While showing a medium growth rate, BFRI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BFRI has reported negative net income.
In the past year BFRI has reported a negative cash flow from operations.
In the past 5 years BFRI always reported negative net income.
In the past 5 years BFRI always reported negative operating cash flow.
BFRI Yearly Net Income VS EBIT VS OCF VS FCFBFRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -82.38%, BFRI is not doing good in the industry: 73.33% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -82.38%
ROE N/A
ROIC N/A
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
BFRI Yearly ROA, ROE, ROICBFRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

With a decent Gross Margin value of 59.02%, BFRI is doing good in the industry, outperforming 66.15% of the companies in the same industry.
BFRI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
BFRI Yearly Profit, Operating, Gross MarginsBFRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BFRI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BFRI has been increased compared to 5 years ago.
BFRI has a worse debt/assets ratio than last year.
BFRI Yearly Shares OutstandingBFRI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
BFRI Yearly Total Debt VS Total AssetsBFRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -9.37, we must say that BFRI is in the distress zone and has some risk of bankruptcy.
BFRI's Altman-Z score of -9.37 is on the low side compared to the rest of the industry. BFRI is outperformed by 67.69% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.37
ROIC/WACCN/A
WACC18.62%
BFRI Yearly LT Debt VS Equity VS FCFBFRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 0.96 indicates that BFRI may have some problems paying its short term obligations.
BFRI's Current ratio of 0.96 is on the low side compared to the rest of the industry. BFRI is outperformed by 83.59% of its industry peers.
A Quick Ratio of 0.75 indicates that BFRI may have some problems paying its short term obligations.
BFRI has a Quick ratio of 0.75. This is amonst the worse of the industry: BFRI underperforms 83.59% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.75
BFRI Yearly Current Assets VS Current LiabilitesBFRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 75.77% over the past year.
Looking at the last year, BFRI shows a quite strong growth in Revenue. The Revenue has grown by 11.18% in the last year.
BFRI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.35% yearly.
EPS 1Y (TTM)75.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1040%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%15.19%

3.2 Future

The Earnings Per Share is expected to grow by 27.87% on average over the next years. This is a very strong growth
Based on estimates for the next years, BFRI will show a very strong growth in Revenue. The Revenue will grow by 22.06% on average per year.
EPS Next Y67.14%
EPS Next 2Y41.94%
EPS Next 3Y27.87%
EPS Next 5YN/A
Revenue Next Year3.38%
Revenue Next 2Y7.22%
Revenue Next 3Y14.55%
Revenue Next 5Y22.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BFRI Yearly Revenue VS EstimatesBFRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
BFRI Yearly EPS VS EstimatesBFRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30 -40 -50

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BFRI. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 13.89, the valuation of BFRI can be described as correct.
Based on the Price/Forward Earnings ratio, BFRI is valued cheaper than 80.51% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.76. BFRI is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 13.89
BFRI Price Earnings VS Forward Price EarningsBFRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BFRI Per share dataBFRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

BFRI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BFRI's earnings are expected to grow with 27.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.94%
EPS Next 3Y27.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BFRI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA INC

NASDAQ:BFRI (9/2/2025, 1:48:41 PM)

0.8499

-0.04 (-4.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners15.84%
Inst Owner Change37.23%
Ins Owners3.41%
Ins Owner Change0%
Market Cap9.07M
Analysts82.5
Price Target6.63 (680.09%)
Short Float %1.42%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.69%
Min EPS beat(2)-114.32%
Max EPS beat(2)-33.05%
EPS beat(4)0
Avg EPS beat(4)-260.71%
Min EPS beat(4)-880.39%
Max EPS beat(4)-15.06%
EPS beat(8)1
Avg EPS beat(8)-144.87%
EPS beat(12)2
Avg EPS beat(12)-101.29%
EPS beat(16)4
Avg EPS beat(16)-85%
Revenue beat(2)1
Avg Revenue beat(2)-6.77%
Min Revenue beat(2)-20.19%
Max Revenue beat(2)6.66%
Revenue beat(4)1
Avg Revenue beat(4)-10.13%
Min Revenue beat(4)-20.19%
Max Revenue beat(4)6.66%
Revenue beat(8)2
Avg Revenue beat(8)-10.23%
Revenue beat(12)2
Avg Revenue beat(12)-8.43%
Revenue beat(16)2
Avg Revenue beat(16)-7.03%
PT rev (1m)1.96%
PT rev (3m)-38.1%
EPS NQ rev (1m)-36.07%
EPS NQ rev (3m)-27.69%
EPS NY rev (1m)-34.67%
EPS NY rev (3m)-75.16%
Revenue NQ rev (1m)-5.76%
Revenue NQ rev (3m)-13.04%
Revenue NY rev (1m)-0.61%
Revenue NY rev (3m)-6.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.89
P/S 0.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.27
EYN/A
EPS(NY)0.06
Fwd EY7.2%
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS3.67
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.38%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.02%
FCFM N/A
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
F-Score3
Asset Turnover1.95
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.38%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.75
Altman-Z -9.37
F-Score3
WACC18.62%
ROIC/WACCN/A
Cap/Depr(3y)4.46%
Cap/Depr(5y)3.05%
Cap/Sales(3y)0.1%
Cap/Sales(5y)0.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1040%
EPS Next Y67.14%
EPS Next 2Y41.94%
EPS Next 3Y27.87%
EPS Next 5YN/A
Revenue 1Y (TTM)11.18%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%15.19%
Revenue Next Year3.38%
Revenue Next 2Y7.22%
Revenue Next 3Y14.55%
Revenue Next 5Y22.06%
EBIT growth 1Y14.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.76%
OCF growth 3YN/A
OCF growth 5YN/A